Skip to content

Arrowhead Pharmaceuticals

US · ARWR #1569 by market cap Listed 1970
41.37 -2.28 -5.22%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 134.21 Expensive vs history 100th percentile
5-year average 13.44 · #511 of 514 in Biotechnology
P/E ratio -9.35 Expensive vs history 73rd percentile
5-year average -269.07 · forward -8.40
P/S ratio 14.98 In line with history 50th percentile
5-year average 94.60 · forward 22.03 · #201 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Arrowhead Pharmaceuticals (ARWR) 5.85B -8.10 116.21 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value68.33 Economic moatNone UncertaintyVery High

Trading 65.2% below Morningstar's fair value estimate.

Fair value

Arrowhead Pharmaceuticals Inc is assigned a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 30% discount to our quantitative fair value estimate of $68.33 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's balance sheet bolsters our quantitative valuation. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. For example, the firm's EBITDA/interest coverage ratio of -2.0 ranks in the bottom 20% compared with global peers. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be undervalued.

Alternatively, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -3.4%, a core component of profitability, sits in the bottom 20% compared with global peers. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Arrowhead Pharmaceuticals discussion 0 comments

Add a comment